Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Antacids could benefit brachycephalic dogs undergoing surgery
Researchers assessed the effects of antacids on brachycephalic dogs before, during and after treatment.

"Treated animals seem to improve faster and have lower clinical scores after surgery than untreated animals" - Dr Emilie Vangrinsven.

Giving antacids to brachycephalic dogs undergoing surgery could result in better treatment outcomes, according to new research.

The study, published in the Journal of Small Animal Practice (JSAP), assessed the effects of antacid treatments (omeprazole (omeprazole (1mg/kg PO q24 hours) and magaldrate (5-10mL/dog PO q8-12 hours) on dogs with brachycephalic syndrome. 

JSAP editor Nicola Di Girolamo said: “Based on this study, antacid treatment administered to brachycephalic dogs undergoing surgery may be beneficial. It should be noted that a direct influence of antacid treatment on digestive clinical and lesion scores could not be significantly demonstrated, which may have been because of the lack of an actual difference, or as a result of the small sample size.”

In the study, 18 dogs were randomly prescribed antacids while 18 other dogs did not receive any gastrointestinal medical treatment. Digestive clinical signs and gastro-oesophageal junction abnormalities (GJA) were assessed and scored at presentation, at the time of surgery and at recheck.

Researchers also assessed GJA during endoscopy under standard conditions and during endotracheal tube obstruction. A single, blinded reviewer recorded and reviewed all endoscopic procedures. 

The procedure was also performed in a control group of 10 dogs to see if endotracheal tube obstruction manoeuvre accurately detects GJA. Healthy control dogs were anaesthetised for independent purposes.

Corresponding author Dr Emilie Vangrinsven said: “Although results of multivariate analysis failed to demonstrate a direct effect of antacid treatment, a significant interaction between antacid treatment status and improvement of digestive clinical score throughout the endoscopies was present, meaning that treated animals seem to improve faster and have lower clinical scores after surgery than untreated animals. Furthermore, a significant improvement in GJA-obstruction score was present in the treatment group only.

“In contrast to standard endoscopy, the obstruction manoeuvre during endoscopy allowed detection of GJA in dogs, even in the absence of clinical signs. We were concerned that the obstruction manoeuvre may induce false-positive results for the diagnosis of dynamic GJA; in the control group, GJA during obstruction manoeuvre were found to be negligible suggesting that this technique does not significantly overestimate the presence of GJA.”

Image (C) Ian Ramsey.

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
Lords Committee opens Pet Parasite Medication inquiry

The House of Lords Environment and Climate Change Committee will launch its inquiry into Pet Parasite Medication (PPM) on Wednesday (3 June).

Focusing on treatments containing fipronil and imidacloprid, the inquiry will seek to understand distribution pathways and the impacts of PPM use and non-use on biodiversity and human health. It will also cover current regulation, monitoring, and the potential implications for pets and their owners.

The committee will hear evidence from environmental non-governmental organisations and research institutes. The public can follow the proceedings live on Parliament TV or in person in the Palace of Westminster.